Quantifying Physical and Biochemical Factors That Contribute to Primary Graft Dysfunction After Lung Transplantation

Measurement of Physical and Biochemical Markers of Reperfusion Edema During Primary Graft Dysfunction Following Lung Transplantation. Assessment of Their Diagnosis and Prognosis Values

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01151826

Enrollment

Registered

2010-06-28

Start date

2010-07-31

Completion date

2012-08-31

Last updated

2011-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Graft Dysfunction

Keywords

Lung transplantation, Primary Graft Dysfunction, Extravascular Lung Water, Receptor for Advanced Glycation Endproducts (RAGE), Intercellular Adhesion Molecule-1 (ICAM-1)

Brief summary

Primary graft dysfunction (PGD or lung reperfusion edema) complicates 10 to 20% of lung transplantations and leads to severe early and late postoperative complications. Its pathophysiology remains unclear but may involve graft ischemia-reperfusion, increased vascular permeability, pneumocyte dysfunction and finally alveolar flooding that impair gas exchange and blood oxygenation.Its substrate, namely extravascular lung water (EVLW), can now be clinically measured with minimally invasive Intensive Care Unit monitors (PiCCO2®, Pulsion Medical Systems) that also provides a physical estimate of pulmonary vascular permeability (PVPI). Similarly, biochemical correlates of vascular permeability (ICAM-1) and pneumocyte dysfunction (RAGE) can now be measured in plasma samples. Our study aims at quantifying physical and biochemical markers of PGD and assess their diagnosis and prognosis values.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Lung transplant recipient * Age \> 18 years * Signed informed consent * Social security affiliation

Exclusion criteria

* Age\<18 * Pregnancy or lactation * Contraindication to femoral arterial catheterization * Patient refusal

Design outcomes

Primary

Measure	Time frame
Diagnosis and prognosis values of extravascular lung water (EVLW) and pulmonary vascular permeability index (PVPI).	H0 (At started lung transplantation), H6, H12, H24, H48, H72 after lung transplantation

Secondary

Measure	Time frame
Diagnosis and prognosis values of receptor for advanced glycation endproducts (RAGE) and intercellular adhesion	H0 (At started lung transplantation), H6, H12, H24, H48, H72 after lung transplantation

Countries

France

Contacts

Primary ContactJulien Pottecher, MD

julien.pottecher@chru-strasbourg.fr33 3 69 55 04 44

Outcome results